A CASE STUDY ON OLIGOHYDRAMNIOS

Submitted By:
BJ ADETTE J. HILARIO
BSN III- Blk.3

Submitted To:
Clinical Instructor Fe Adriano RN, MAN.

Oligohydramnios is a condition in pregnancy characterized by a deficiency of amniotic fluid. The common clinical features are smaller symphysio fundal height, fetal malpresentation, undue prominence of fetal parts and reduced amount of amniotic fluid. It is typically caused by fetal urinary tract abnormalities such as unilateral renal agenesis ( Potter’s syndrome ), fetal polycystic kidneys, or genitourinary obstruction. Uteroplacental insufficiency is another common cause. Most of these abnormalities can also be detected by obstetric ultrasound. It may also occur simply due to dehydration of the mother, maternal use of angiotensin converting enzyme inhibitors, or without a determinable cause (idiopathic).

a. Information

i. Name: Jocelyn TapangJapones
ii. Age: 32 years old
iii. Gender: Female
iv. Birthday: August 17, 1980
v. Birth place: General Natividad
vi. Marital Status: Married
vii. Address: 149, Balangkare Norte, General Natividad, Nueva Ecija
viii. Occupation: N/A
ix. Religion: Iglesia Ni Cristo
x. Nationality: Filipino
xi. Spouse Name: Herb Japones
xii. Father’s Name: Alfredo Tapang
xiii. Mother’s Name: AdelinaTapang

b. Admission Record
Admitting Date: 22-Nov-2012
Admitting Time: 2:35am
Attending Physician: Amorin, Edeliza MD
c. Initial diagnosis:

G4P1, (1021), PU 36 5/7 weeks AOG, Oligohydramnios

d. Final diagnosis:

G4P2 (1102) delivered operatively to a live, preterm baby girl/ BW= 1.9kg, APAS, uterine varicosities; Oligohydramnios

e. Operation Performed:

Lower Transverse Cesarean Section (LTCS) (midline)

f. History of Present Illness

G4P1 (1021).Known case of APAS during this pregnancy. On regular PNCU today, (+) Oligohydramnios noted on ultrasound. Advised primary LTCS.

g. Past Medical/ Health History

Unremarkable
(+) Hypertension
(+) Diabetes Mellitus

h. OB-Gyne History

G4P1 (1021)
AOG 36 5/7 weeks
LMP 3/10/2012

i. Allergies:

SMC, Celecoxib

a. Course of Confinement

i. Medications administered since date of admission
Physician’s Order:
METRONIDAZOLE 500mg every 8 hours intravenously

KETOROLAC 30mg every 8 hours as necessary for pain intravenously

METRONIDAZOLE 500mg/tablet 1 tablet 3x a day per orem

CEFUROXIME 5oomg/capsule 1 capsule 2x a day per orem

TRAMADOL 37.5, PARACETAMOL 325mg (Algesia)/tablet 1 tablet 3x a day round the clock per orem

ii. IVF, BT and other parenteral medication infused/administered since date of admission

IVF: D5LRS 1L for 8 hours 41-42 gtts/min

iii. All diagnostic tests made to patient since date of admission

Variables
Normal Value
Result
Hemoglobin
Male: 130-170 g/L
Female: 120-150 g/L
135
Hematocrit
Male: 0.40-0.50
Female: 0.37-0.45
0.43
Red Cell Count
Male: 4.5-5.5 x10 12/L
Female: 4.6-5.2 x10 12/L
6.02 x10 1/L
White Cell Count
5-10 x10g/L
18.52 x10g/L
Platelet Count
Manual: 150-400 x10/L
Machine: 130-500 x10/L
__ x10/L
Nucleated RBC/100WBC

Reticulocyte CT

MCV

MCH

MCHC

RDW CV

Adult: 0.5%-1.5%
Newborn: 2.0%-6.0%

80-100fl

27-31

32-36 g/dL

11.6-14.6%

72.8fl

22.4

30.8 g/dL

17.1%
Differential Count

Neutrophils

Lymphocytes

Monocytes

Eosinophils

Basophils

Stabs

Others

0.55-0.65

0.25-0.35

0.02-0.06

0.02-0.04

0-0.005

0-0.05

0.89

0.09

0.02

iv. Other relevant events during hospitalization

* None.

b. Physical Assessment

i. General Appearance:
* Ambulatory
* Coherent

ii. Weight and Vital Signs
* Weight-58 kg.
* Vital Signs-
* Blood Pressure- 110/80 mmHg
* Temperature- 36.8°C
* Pulse Rate- 72bpm
* Respiratory Rate- 18bpm

iii. HEENT:
* Pink, PC, AS

iv. Neurologic Exam:
* E/N

v. Chest and Lungs:
* SCE, CBS

vi. Heart:
* AP NRRR

vii. Abdomen:
* Soft, round, FHT

viii. Extremities:
* Pulses, full and equal

Amniotic fluid is a clear, slightly yellowish liquid that surrounds the unborn baby (fetus) during pregnancy. It is contained in the amniotic sac.While in the womb, the baby floats in the amniotic fluid. The amount of amniotic fluid is greatest at about 34 weeks (gestation) into the pregnancy, when it averages 800 mL. Approximately 600 mL of amniotic fluid surrounds the baby at full term (40 weeks gestation).
The amniotic fluid constantly moves (circulates) as the baby swallows and “inhales” the fluid, and then releases it.
The amniotic fluid helps:
* The developing baby to move in the womb, which allows for proper bone growth
* The lungs to develop properly
* Keep a relatively constant temperature around the baby, protecting from heat loss
* Protect the baby from outside injury by cushioning sudden blows or movements
An excessive amount of amniotic fluid is called polyhydramnios. This condition can occur with multiple pregnancy (twins or triplets), congenital anomalies (problems that exist when the baby is born), or gestational diabetes.
An abnormally small amount of amniotic fluid is known as oligohydramnios. This condition may occur with late pregnancies, ruptured membranes, placental dysfunction, or fetal abnormalities.
Abnormal amounts of amniotic fluid may cause the health care provider to watch the pregnancy more carefully. Removal of a sample of the fluid, through amniocentesis, can provide information about the sex, health, and development of the fetus.

* Close medical supervision of the mother and fetus.
* Fetal monitoring
* Amnioinfusion (infusion of warmed sterile normal saline or lactated Ringer’s solution) to treat or prevent variable decelerations during labor.

1. Monitor maternal and fetal status closely, including vital signs and fetal heart rate patterns.
2. Monitor maternal weight gain pattern, notifying the health care provider if weight loss occurs.
3. Provide emotional support before, during, and after ultrasonography.
4. Inform the patient about coping measures if fetal anomalies are suspected.
5. Instruct her about signs and symptoms of labor, including those she’ll need to report immediately.
6. Reinforce the need for close supervision and follow up.
7. Assist with amnioinfusion as indicated.
8. Encourage the patient to lie on her left side.
9. Ensure that amnioinfusion solution is warmed to body temperature.
10. Continuously monitor maternal vital signs and fetal heart rate during the amnioinfusion procedure.
11. Note the development of any uterine contractions, notify the health care provider, and continue to monitor closely.
12. Maintain strict sterile technique during amnioinfusion.